Publications

Here you will find the most relevant publications about APO010 and the science behind.

More news releases from Oncology Venture.

May 0
May 0

OV‘s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug

Hoersholm, Denmark, May 31th 2017 Press release Hoersholm, Denmark, May 31th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that the first patient has entered the APO010 Phase 1/2 study for Multiple Myeloma (MM). APO010 is a first-in-class FAS- ligand anticancer product in immuno-oncology (“IO”). The DRPTM (Drug Response Predictor) Screening for sensitive patients […]

  Read more
Mar 0
Mar 0

Green light to Oncology Venture for DRP focused clinical APO010 study in Multiple Myeloma

Hoersholm, Denmark, March 21th 2017 Press release Hoersholm, Denmark, March 21th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that the Danish Medicines Agencies (DHMA) have approved the focused APO010 Multiple Myeloma study. APO010 is a first-in-class FAS-ligand anticancer product in the immuno-oncology field. The DRP Screening for sensitive patients at four centers of […]

  Read more
Oct 0
Oct 0

Poster on Immuno Oncology APO010 sensitivity in Multiple Myeloma presented at European Society of Medical Oncology (ESMO)

Hoersholm, Denmark, October 10th 2016 Press release Poster # 134P: APO010 sensitivity in relapsed Multiple Myeloma patients is presented in Hall E, today: October 10th 2016 at 13-14 CET at ESMO. Please see the attached Poster. Please see the attached Poster. For the related abstract – please refer to: the ESMO website http://www.esmo.org/ as previously […]

  Read more
Jun 0
Jun 0

Oncology Venture’s immuno-oncology drug APO010 for Multiple Myeloma receives EUROSTARS grant of a total value of 12,7 mNOK from Norway

Hørsholm, Denmark June 17, 2016 Press release Hoersholm, Denmark; June 17th, 2016 – Oncology Venture Sweden AB (OV:ST) announces that up to 6 million NOK (app. 632,000 EUR) has been granted by the Norwegian Research Council through the EUROSTARS program for the development of Oncology Venture’s immuno-oncology product APO010. The grant will i.a. cover the […]

  Read more
Mar 0
Mar 0

First Patient Included in OV’s APO010 Screening Study

Hoersholm, Denmark, March 10th 2016 Press release Hoersholm, Denmark, March 10th, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that the first patient has been included in the screening protocol for APO010 in Multiple Myeloma. This patient has entered the study at the first out of four planned participating Danish hematology sites where approximately […]

  Read more
Mar 0
Mar 0

Oncology Venture’s APO010 screening protocol approved

Hoersholm, Denmark, 03 March 2016 Press release Hoersholm, Denmark; March 3rd, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that the screening protocol for APO010 in Multiple Myeloma (MM) has been approved by the Ethics Committee. APO010 is a first in class FASLigand anticancer product in the immuno-oncology field. OV will now initiate the […]

  Read more
Dec 0
Dec 0

Oncology Venture has submitted the APO010 screening protocol

Hoersholm, Denmark; December 18th, 2015 Press release Oncology Venture Sweden AB (OV:ST) announces that the screening protocol for APO010 in Multiple Myeloma (MM) has been submitted to the Ethics Committee. APO010 is a first in class FASLigand anticancer product in the immuno oncology field. OV will screen approximately 150 patients and identify 15 patients with […]

  Read more
Sep 0
Sep 0

OV has incorporated its APO010 DRP(TM) in its clinical program

Hoersholm, Denmark, 30 September 2015 Press release Oncology Venture announces that it has incorporated the APO010 Drug Response Predictor – (APO010 DRPTM) from MPI A/S into its clinical development program. Based on the DRP it has been decided to develop APO010 into the treatment of multiple myeloma. The DRPTM will consequently be used in the […]

  Read more